跳至主要内容
临床试验/NCT01698970
NCT01698970已完成不适用

Effect of the Consumption of a Probiotic Strain on the Prevention of Post-operative Recurrence in Crohn's Disease

Danone Research2 个研究点 分布在 1 个国家目标入组 122 人开始时间: 2004年2月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
122
试验地点
2

研究概览

简要总结

A double-blind, multicentre, stratified by centre, randomised, parallel study with two groups of adult patients operated on for Crohn's disease, to determine if oral ingestion of probiotics could prevent the appearance of Crohn's disease recurrent endoscopic ileo-colonic lesions 12 months after surgery. Patients will consume 900 mg/day of active product (N=56) or control product (N=56) during one year.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male/female at least 18 years old
  • Diagnosis of Crohn's disease defined by the criteria usually adopted (Gower-Rousseau, 1994)
  • Crohn's disease mainly limited to the terminal ileum and/or the ascending and transverse colon
  • Diagnosis of Crohn's disease in agreement with surgical specimen analysis
  • Patient having given its written consent to take part in the study
  • Complete resection of all main macroscopic ileo-colonic lesions, as shown by inspection at surgery
  • To have an ileo-colic resection (right, transverse, left) with an anastomosis that can be inspected by endoscopy
  • Ability to start oral nutrition and therefore the consumption of the study product within 21 days of surgery
  • Patient receiving no antibiotics at the beginning of the product consumption

排除标准

  • One or more intestinal resection during the 5 last years before the last surgery
  • Presence of any severe additional disease
  • For female patient : pregnancy or breast feeding
  • For pre-menopausal female patient : no effective contraceptive methods used (combined oestrogen-progestogen pill or Intrauterine Device)
  • Patient currently in an exclusion period following participation in another clinical trial
  • Patient in a situation which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the patient
  • Significant presence of Crohn's disease in other intestinal tracts
  • Small bowel cumulative resection exceeding 1 meter
  • Patient with ileostomy
  • Subtotal colectomy with ileo-rectal anastomosis
  • Severe post-operative septic complications (fistula, peritonitis), leading to administration of more than 15 days of post-operative antibiotherapy)
  • Intake of unauthorised treatments (mesalazine, olsalazine or sulfasalazine, 5-Aminosalicylates (5-ASA) or 4-Aminosalicylates (4-ASA)) ; corticoïds and immunosuppressors) after surgery except corticoids which will have to be stopped within 6 weeks after surgery according to standardised stepwise dose reductions
  • Patient under artificial nutrition
  • Subject with a loss of personal liberty, by administrative or judicial decision, or major with a legal guardian

研究者

发起方
Danone Research
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验